Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...
We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Shares of Merck & Co. Inc. fell more than 0.5% on Monday afternoon, tracking their fifth consecutive decline in the worst ...
They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...